Anterior gradient-2
protein was identified using proteomic technologies as a p53 inhibitor which is overexpressed in human
cancers, and this
protein presents a novel pro-oncogenic target with which to develop diagnostic assays for
biomarker detection in clinical tissue. Combinatorial phage-
peptide libraries were used to select 12
amino acid polypeptide aptamers toward anterior gradient-2 to determine whether methods can be developed to affinity purify the
protein from clinical biopsies. Selecting phage aptamers through four rounds of screening on recombinant human anterior gradient-2
protein identified two classes of
peptide ligand that bind to distinct
epitopes on anterior gradient-2
protein in an immunoblot. Synthetic biotinylated
peptide aptamers bound in an ELISA format to anterior gradient-2, and substitution mutagenesis further minimized one
polypeptide aptamer to a hexapeptide core. Aptamers containing this latter consensus sequence could be used to affinity purify to homogeneity human anterior gradient-2
protein from a single clinical biopsy. The
spotting of a panel of
peptide aptamers onto a
protein microarray matrix could be used to quantify anterior gradient-2
protein from crude clinical biopsy lysates, providing a format for quantitative screening. These data highlight the utility of
peptide combinatorial libraries to acquire rapidly a high-affinity
ligand that can selectively bind a target
protein from a clinical biopsy and provide a technological approach for clinical
biomarker assay development in an aptamer microarray format.